Skip to content

CMS decision not to cover Alzheimer’s treatment a bad one

CMS decision not to cover Alzheimer’s treatment a bad one NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease.  Restricting coverage is a bad idea…

Read More